v3.24.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 1,783 $ 8,836
Accounts receivable   268
Research and development tax credit receivable 1,163 610
Prepaid expenses and other current assets 804 811
Total current assets 3,750 10,525
Property, plant and equipment, net 353 455
Right-of-use assets, net 197 285
Other assets, non-current 6 7
Total assets 4,306 11,272
Current liabilities    
Accounts payable and accrued expenses 1,463 1,178
Lease liabilities, current 165 230
Other current liabilities 367 360
Total current liabilities 1,995 1,768
Lease liabilities, non-current 31 19
Warrant liability   1,372
Total liabilities 2,026 3,159
Commitments and contingencies (Note 7)
Stockholders' equity:    
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, 856 and 13,765 shares issued and outstanding, at September 30, 2024 and December 31, 2023, respectively
Common stock, par value $0.0001 per share, 300,000,000 shares authorized, 1,780,472 and 889,668 shares issued and outstanding, at September 30, 2024 and December 31, 2023, respectively
Additional paid-in capital 113,374 104,757
Accumulated other comprehensive loss (1,297) (1,578)
Accumulated deficit (109,797) (95,066)
Total stockholders' equity 2,280 8,113
Total liabilities and stockholders' equity $ 4,306 $ 11,272

Source

HTML PDF
ZIP